CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 84 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q4 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $80,000 | -81.2% | 44,601 | -12.0% | 0.04% | -79.1% |
Q2 2020 | $425,000 | +13.6% | 50,694 | -28.9% | 0.20% | +30.5% |
Q1 2020 | $374,000 | -16.1% | 71,343 | -12.7% | 0.15% | +111.0% |
Q4 2019 | $446,000 | +147.8% | 81,751 | +121.7% | 0.07% | +102.8% |
Q3 2019 | $180,000 | -33.3% | 36,881 | -5.3% | 0.04% | -36.8% |
Q2 2019 | $270,000 | -4.3% | 38,935 | -4.2% | 0.06% | -90.5% |
Q1 2019 | $282,000 | +4.8% | 40,628 | -12.0% | 0.60% | +1204.3% |
Q4 2018 | $269,000 | -54.0% | 46,147 | -40.4% | 0.05% | -23.3% |
Q3 2018 | $585,000 | -12.8% | 77,428 | -41.7% | 0.06% | -89.9% |
Q2 2018 | $671,000 | +7.4% | 132,890 | +29.7% | 0.59% | +9.4% |
Q1 2018 | $625,000 | +85.5% | 102,493 | +116.1% | 0.54% | +28.1% |
Q4 2017 | $337,000 | -15.8% | 47,426 | -15.2% | 0.42% | +683.3% |
Q3 2017 | $400,000 | +25.0% | 55,909 | +10.1% | 0.05% | +12.5% |
Q2 2017 | $320,000 | +19.4% | 50,795 | +56.1% | 0.05% | 0.0% |
Q1 2017 | $268,000 | +7.6% | 32,545 | +10.6% | 0.05% | -35.1% |
Q4 2016 | $249,000 | – | 29,425 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 5,045,870 | $1,273,000 | 0.73% |
ETF MANAGERS GROUP, LLC | 7,062,485 | $1,787,000 | 0.05% |
Ikarian Capital, LLC | 862,527 | $217,000 | 0.04% |
IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 457,209 | $115,000 | 0.02% |
Platform Technology Partners | 33,750 | $9,000 | 0.01% |
PINNACLE ASSOCIATES LTD | 910,006 | $230,000 | 0.01% |
CJM Wealth Advisers, Ltd. | 30,465 | $7,683 | 0.01% |
Mirae Asset Global Investments Co., Ltd. | 4,029,171 | $1,016,000 | 0.00% |
Vident Investment Advisory, LLC | 267,612 | $67,000 | 0.00% |
Aries Wealth Management | 15,400 | $4,000 | 0.00% |